AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- The meningococcal serogroup C conjugate vaccine has reduced mortality in Scotland.
According to recent research from Scotland, "The increasing number of cases of serogroup C meningococcal disease in Scotland in the late 1990s coincided with the availability of a new meningococcal conjugate serogroup C (MCC) vaccine that, from 1999 onwards, was offered to all individuals aged
"Dramatic reductions (p
"An increasing incidence of serogroup B meningococcal disease in individuals 5-19 years old was clearly established before the campaign began," concluded Mooney and his collaborators. "A 30% decrease in the case-fatality rate for individuals
Mooney and his coauthors published their study in Clinical Infectious Diseases (The impact of meningococcal serogroup C conjugate vaccine in Scotland. Clin Infect Dis, 2004;39(3):349-356).
For additional information, contact John D. Mooney, Scottish Center for Infection and Environmental Health, University of Strathclyde, Clifton Place, Glasgow G3 7LN, Lanark, Scotland. E-mail: john.mooney@scieh.csa.scot.nhs.uk.
Publisher contact information for the journal Clinical Infectious Diseases is: University of Chicago Press, 1427 East 60th Street, Chicago, IL 60637-2954, USA.